Wikipedia

Draft:Angelo E Gousse M.D.

Angelo E. Gousse
Born
Port-au-Prince, Haiti
Education
  • B.S., City University of New York (York College)
  • M.D., Yale University School of Medicine
Known forEarly clinical trials of intradetrusor botulinum toxin; co-authorship of Phase 3 onabotulinumtoxinA trial; GASHU co-founder
Medical career
Institutions
  • University of Miami Miller School of Medicine (former)
  • Bladder Health & Reconstructive Urology Institute
  • Florida International University (Herbert Wertheim College of Medicine)

Angelo E. Gousse (born in Port-au-Prince, Haiti) is a Haitian-American urologist and academic physician specializing in reconstructive urology, urinary incontinence, artificial urinary sphincter surgery, and penile prosthetic implantation. He is the founder of the Bladder Health & Reconstructive Urology Institute, a multi-site specialty practice in South Florida. Gousse has held academic appointments at the University of Miami Miller School of Medicine and Florida International University's Herbert Wertheim College of Medicine. He has received two of the highest honors of the American Urological Association (AUA): Honorary Membership (2022) and the Distinguished Contribution Award (2024).[1][2]

Early life and education

edit

Gousse was raised in Port-au-Prince, Haiti, and completed his secondary education at Petit Séminaire Collège Saint-Martial. He subsequently emigrated to the United States, graduating as valedictorian from York College of the City University of New York with a perfect grade point average in his major.[3] He received his M.D. cum laude with highest honors from Yale School of Medicine.[4][5]

He completed a urology residency at Baylor College of Medicine in Houston, Texas, followed by a postdoctoral fellowship in urodynamics, female urology, and pelvic floor reconstruction at the University of California, Los Angeles (UCLA) under Dr. Shlomo Raz.[4][5] He holds dual board certification from the American Board of Urology in Urology and in Female Pelvic Medicine and Reconstructive Surgery.[5]

Academic career

edit

In 1999, Gousse joined the faculty of the University of Miami Miller School of Medicine, where he rose to the rank of tenured Professor of Urology. He served as Vice Chair of the Department of Urology, Residency Program Director, and Fellowship Director for Female Urology, Urodynamics, and Reconstructive Surgery for approximately ten years. He also directed the Urodynamics Laboratory at the Miami Veterans Affairs Hospital.[4][6]

He subsequently held an appointment as Clinical Professor of Urology at FIU's Herbert Wertheim College of Medicine and Fellowship Director at Memorial Hospital Miramar, South Broward Hospital District.[7]

Gousse served on the AUA Clinical Guidelines Committee, the AUA Female Urology Core Curriculum Committee, and as Section Editor of the Female Urology section of Current Urology Reports. He serves as a reviewer for The Journal of Urology, Neurourology and Urodynamics, and Urology.[8] He chaired the 2014 joint AUA–SUFU annual meeting and represented the AUA as keynote speaker at the centennial of the Association Française d'Urologie in Paris. He has served on the executive boards of the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) and the Genitourinary Reconstructive Surgeons (GURS) society.[7]

Medical research and clinical contributions

edit

Botulinum toxin for bladder dysfunction

edit

Gousse was among the first urologists in the United States to offer sacral neuromodulation (InterStim) beginning in 1998, and he pioneered botulinum toxin injections into the detrusor for neurogenic and idiopathic overactive bladder beginning in 2000.[9] His investigator-initiated clinical studies contributed to the first FDA approval of onabotulinumtoxinA (Botox) for a urologic indication — neurogenic detrusor overactivity — in August 2011.[9][10][11]

Gousse co-authored a pivotal, multi-institutional, double-blind Phase 3 clinical trial of onabotulinumtoxinA for urinary incontinence resulting from neurogenic detrusor overactivity, published in The Journal of Urology in 2012, which enrolled 416 patients across multiple international sites and contributed directly to the FDA's approval of that indication:[12] He also co-authored clinical trials leading to FDA approval of mirabegron (Myrbetriq), the first beta-3 adrenergic agonist approved for overactive bladder.[13]

His research group published findings on optimal dosing strategies for intradetrusor botulinum toxin, including a dose-finding study comparing 100 versus 150 units in idiopathic overactive bladder patients, and a prospective trial demonstrating the safety and efficacy of repeat onabotulinumtoxinA injections in neurogenic overactive bladder patients.[14]

Reconstructive urology

edit

Gousse's publication record in reconstructive urology includes peer-reviewed studies on artificial urinary sphincter implantation and outcomes following radical prostatectomy. Among the most frequently cited is:[15] This work has been cited in systematic reviews of artificial urinary sphincter outcomes.[16]

In April 2024, Gousse authored an article in AUA News at the request of the American Urological Association, commemorating his Distinguished Contribution Award and detailing his ongoing bioengineering research on a Bluetooth-enabled artificial urinary sphincter.[17]

Awards and recognition

edit

Gousse has received two of the highest honors conferred by the American Urological Association: AUA Honorary Membership (2022) and the AUA Distinguished Contribution Award (2024), the latter awarded for dedicated research in treating voiding dysfunction and overactive bladder.[1][2] He has been listed in Best Doctors in America for fifteen consecutive years, and in U.S. News & World Report's Best Doctors listing. Additional recognitions include the Pfizer Scholars in Urology Award, the Cullen Research Award from Baylor College of Medicine, the Jonas Salk Scholar Award, and the Coloplast Penile Implant Center of Excellence Award.[5][18]

Global philanthropic work and Haitian urology

edit

Through the Global Philanthropic Committee in Urology (GPC), Gousse serves as the AUA liaison to the Global Association for the Support of Haitian Urology (GASHU), which he co-founded in 2016 with a group of Haitian and international urologists after organizing the first Haitian-American Urology Conference in Haiti in 2014.[19][20] GASHU's mission is to advance urologic training, education, and care in Haiti in coordination with Haitian and international urological organizations.[21]

Gousse has chaired GASHU's annual international urology conferences in Haiti and instituted a fellowship program at his Florida-based institute that has trained young Haitian urologists from Haiti on a rolling basis for over a decade.[22] A strategy for rapidly advancing urology in resource-limited countries, developed from the GASHU model, has been published in medical journals and presented at international meetings.[22]

Community engagement

edit

Within the Haitian community of South Florida, Gousse hosts the Creole-language radio program Konsiltasyon Urologik an Kreyòl on Radio Mega 1700 AM and has hosted television health programs on Island TV. He has authored a urology health column in Le Floridien newspaper.[7] He co-founded and served as president of the Haitian American Leadership Organization (HALO) for approximately a decade, and has served as President of the Haitian Medical Association Abroad (AMHE), South Florida Chapter.[8] As inaugural President of Angels for Humanity, he has participated in medical and humanitarian missions to Haiti, the Dominican Republic, and Central America.[13]

Selected peer-reviewed publications

edit
  • Ginsberg D, Gousse A, et al. "Phase 3 efficacy and tolerability study of onabotulinumtoxinA in patients with urinary incontinence resulting from neurogenic detrusor overactivity." The Journal of Urology 187, no. 6 (2012): 2131–2139. doi:10.1016/j.juro.2012.01.125 PMID 22503020
  • Gousse AE, Madjar S, Lambert MM, Fishman IJ. "Artificial urinary sphincter for post-radical prostatectomy urinary incontinence: long-term subjective results." The Journal of Urology 166, no. 5 (2001): 1755–1758. doi:10.1097/00005392-200111000-00031
  • Madjar S, Raz S, Gousse A. "Fixed and dynamic urethral compression for the treatment of post-prostatectomy urinary incontinence." Journal of Urology 166, no. 2 (2001): 411–415.
  • Gousse A, Kanagarajah P, Ayyathurai R, et al. "Repeat Intradetrusor Injections of Onabotulinum Toxin A for Refractory Idiopathic Overactive Bladder Patients." Female Pelvic Medicine & Reconstructive Surgery 17, no. 5 (2011): 253–257. doi:10.1097/SPV.0b013e31822f816f
  • Gomez C, Kanagarajah P, Gousse A. "The Use of Botulinum Toxin A in Idiopathic Overactive Bladder Syndrome." Current Urology Reports (2010). doi:10.1007/s11934-010-0134-4

References

edit
  1. 1 2 "AUA Announces 2024 Distinguished Awards Recognizing Top Urologists" (Press release). GlobeNewswire. December 4, 2023. Retrieved June 2026. {{cite press release}}: Check date values in: |access-date= (help)
  2. 1 2 "AUA 2024". Baylor College of Medicine. June 2024. Retrieved June 2026. {{cite web}}: Check date values in: |access-date= (help)
  3. ↑ HaitiOpen 2020.
  4. 1 2 3 "Dr. Angelo Gousse, MD — Profile". Zocdoc. Retrieved June 2026. {{cite web}}: Check date values in: |access-date= (help)
  5. 1 2 3 4 "Angelo E. Gousse, M.D.: A Haitian Academic Urologist". Haiti Open. January 23, 2020. Retrieved June 2026. {{cite web}}: Check date values in: |access-date= (help)
  6. ↑ "Gousse, Angelo E. — Provider Profile". Memorial Healthcare System. Retrieved June 2026. {{cite web}}: Check date values in: |access-date= (help)
  7. 1 2 3 "Dr. Angelo E. Gousse: A Leading Urologist in Our Community". Le Floridien. 9 January 2019. Retrieved June 2026. {{cite web}}: Check date values in: |access-date= (help)
  8. 1 2 "A New Executive Board of the AMHE — Florida Chapter Voted Dr. Angelo E. Gousse President". Le Floridien. 15 August 2021. Retrieved June 2026. {{cite web}}: Check date values in: |access-date= (help)
  9. 1 2 "Gousse Urology — About". Bladder Health & Reconstructive Urology Institute. Retrieved June 2026. {{cite web}}: Check date values in: |access-date= (help)
  10. ↑ Schulte-Baukloh, Heinrich (2025). "Assessing the Use of BotulinumtoxinA for Hyperactive Urinary Tract Dysfunction a Decade After Approval". Toxins. 17 (7): 351. doi:10.3390/toxins17070351. PMC 12300746. PMID 40711162. Botulinum toxin was approved by the Food and Drug Administration in 2011 for neurogenic bladder and in 2013 for idiopathic overactive bladder.
  11. ↑ Bosch, Ruud (2023). "Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact". Neurourology and Urodynamics. 102 (S1): e32377. doi:10.1002/nau.25229. PMC 10374192. PMID 37499088. Early positive results from pioneering investigators caught the interest of Allergan, which initiated collaborative clinical trials resulting in FDA approval of onabotulinumtoxinA 200U in 2011 for NDO.
  12. ↑ Ginsberg, David; Gousse, Angelo; Keppenne, Veronique (2012). "Phase 3 efficacy and tolerability study of onabotulinumtoxinA in patients with urinary incontinence resulting from neurogenic detrusor overactivity". The Journal of Urology. 187 (6): 2131–2139. doi:10.1016/j.juro.2012.01.125. PMID 22503020. {{cite journal}}: Invalid |display-authors=3 (help)
  13. 1 2 "Dr. Angelo Gousse". Angels for Humanity. July 2025. Retrieved June 2026. {{cite web}}: Check date values in: |access-date= (help)
  14. ↑ "Angelo Gousse — Research Profile". Retrieved June 2026. {{cite web}}: Check date values in: |access-date= (help)
  15. ↑ Gousse, A.E.; Madjar, S.; Lambert, M.M.; Fishman, I.J. (2001). "Artificial urinary sphincter for post-radical prostatectomy urinary incontinence: long-term subjective results". The Journal of Urology. 166 (5): 1755–1758. doi:10.1097/00005392-200111000-00031. PMID 11586217.
  16. ↑ Montague, D.K. (2012). "Artificial Urinary Sphincter: Long-Term Results and Patient Satisfaction". Advances in Urology: 835290. doi:10.1155/2012/835290. PMC 3254001. PMID 22242021.{{cite journal}}: CS1 maint: article number as page number (link)
  17. ↑ Gousse, Angelo E. (April 19, 2024). "AUA Award Winners: The Quest for a Novel Bluetooth Artificial Urinary Sphincter". AUA News. Retrieved June 2026. {{cite web}}: Check date values in: |access-date= (help)
  18. ↑ "Dr. Angelo Gousse, MD — Physician Profile". Healthgrades. Retrieved June 2026. {{cite web}}: Check date values in: |access-date= (help)
  19. ↑ Gousse, Angelo E. (October 2021). "The Growth of Urology Volunteerism in Haiti and Its Vital Role". Le Floridien / European Urology Association. Retrieved June 2026. {{cite journal}}: Check date values in: |access-date= (help)
  20. ↑ "SHU and St. François de Salles Memorandum of Understanding". Project Haiti. Retrieved June 2026. {{cite web}}: Check date values in: |access-date= (help)
  21. ↑ "Urology is Taking Off in Haiti". Haiti Open. January 15, 2020. Retrieved June 2026. {{cite web}}: Check date values in: |access-date= (help)
  22. 1 2 "Angelo Gousse, MD". Haitian Medical Association Abroad — Florida Chapter. Retrieved June 2026. {{cite web}}: Check date values in: |access-date= (help)
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Draft:Angelo_E_Gousse_M.D.&oldid=1357650991"